Bellevue Life Sciences Acquisitions Corp. Reminds Stockholders to Vote in Favor of Extension at May 14, 2024 Stockholder Meeting
Bellevue Life Sciences Acquisitions Corp. (BLAC) has announced a Special Meeting to vote on extending the deadline for a business combination with OSR Holdings Co., , a healthcare holding company based in South Korea. Stockholders are encouraged to vote in favor of the Extension Amendment Proposal to extend the deadline from May 14, 2024, to November 14, 2024. Failure to secure at least 65% of votes may lead to liquidation and missed opportunities for stockholders.
- None.
- None.
BLAC encourages stockholders to vote in favor of the proposal to extend the date by which BLAC has to consummate a business combination from May 14, 2024 to November 14, 2024 (the "Extension Amendment Proposal") at its Special Meeting. The purpose of the Extension Amendment Proposal is to allow BLAC more time to complete its previously announced business combination with OSR Holdings Co., Ltd. ("OSR Holdings"), a global healthcare holding company based in
Should BLAC not receive votes representing at least
Every stockholder's vote is important, regardless of the number of shares the stockholder holds. BLAC requests that each stockholder promptly submit its proxy votes electronically or by telephone (if those options are available to you) in accordance with the instructions on the enclosed proxy card or voting instruction card.
BLAC strongly recommends that stockholders submit their proxies electronically or by telephone by 11:59p.m. ET on May 13, 2024, the day before the Special Meeting, to ensure that their shares will be represented at the Special Meeting. Further instructions on how to vote stockholder shares are in the proxy materials that were mailed to stockholders on or about April 30, 2024 in connection with the Special Meeting.
If stockholders have any questions or need assistance voting their shares, please contact Advantage Proxy, BLAC's proxy solicitor, by calling toll-free at 1-877-870-8565 or collect at 1-206-870-8565 or by email to ksmith@advantageproxy.com.
Reversal of Redemption Requests
In light of the adjournment of the Special Meeting, any stockholder who has previously tendered its shares for redemption and now decides that it does not want to redeem its shares, the stockholder may still withdraw the tender. If you delivered your shares for redemption to the transfer agent and decide prior to the vote at the Special Meeting (now scheduled for 9:00 a.m. Pacific time on May 14, 2024) not to redeem your public shares, you may request that the transfer agent return the shares (physically or electronically). You may make such request by contacting the transfer agent at:
Continental Stock Transfer & Trust Company
1 State Street, 30th Floor,
Attn: SPAC Redemption Team
E-mail: spacredemptions@continentalstock.com
Forward-Looking Statements
This press release contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding BLAC's financial position, business strategy and the plans and objectives of management for future operations, including as they relate to a business combination. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. They involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of BLAC to be materially different from any future results, performance or achievements expressed or implied by these statements. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this press release, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When BLAC discusses its strategies or plans, including as they relate to a business combination, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, BLAC's management. Actual results and stockholders' value will be affected by a variety of risks and factors, including, without limitation, international, national and local economic conditions, merger, acquisition and business combination risks, financing risks, geo-political risks, acts of terror or war, and those risk factors described under "Item 1A. Risk Factors" of BLAC's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on April 17, 2024, in the section titled "Risk Factors" contained in our prospectus dated February 9, 2023, and in other reports BLAC files with the SEC. Many of the risks and factors that will determine these results and stockholders' value are beyond BLAC's ability to control or predict.
All such forward-looking statements speak only as of the date of this press release. BLAC expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BLAC's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. All subsequent written or oral forward-looking statements attributable to us or persons acting on BLAC's behalf are qualified in their entirety by this "Forward-Looking Statements" section.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
Participants in the Solicitation
BLAC and its directors, executive officers, other members of management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies from the securityholders of BLAC in favor of the approval of the proposals as described in the Proxy Statement. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of BLAC's directors and officers in the Proxy Statement, which may be obtained free of charge from the sources indicated above.
BLAC, OSR Holdings, and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of BLAC stockholders in connection with the proposed business combination. Investors and security holders may obtain more detailed information regarding the names, affiliations and interests of BLAC's directors and officers in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on April 17, 2024, and its registration statement on Form S-1 for its initial public offering. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to BLAC's stockholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus for the proposed business combination when available. Information concerning the interests of BLAC's and OSR Holdings' equity holders and participants in the solicitation, which may, in some cases, be different than those of BLAC's and OSR Holdings' equity holders generally, will be set forth in the proxy statement/prospectus relating to the proposed business combination when it becomes available.
Additional Information and Where to Find It
BLAC urges investors, stockholders and other interested persons to read the Proxy Statement as well as other documents filed by BLAC with the SEC, because these documents will contain important information about BLAC and the Extension Amendment Proposal. Stockholders may obtain copies of the Proxy Statement, without charge, at the SEC's website at www.sec.gov or by directing a request to: Advantage Proxy, Inc., P.O. Box 10904,
BLAC will prepare a proxy statement/prospectus to be filed with the SEC and mailed to BLAC's stockholders. BLAC and OSR Holdings urge investors and other interested persons to read, when available, the proxy statement/prospectus prepared for the proposed business combination, as well as other documents filed by BLAC with the SEC, because these documents will contain important information about the proposed business combination. Such persons can also read BLAC's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and its registration statement on Form S-1 for its initial public offering, all as filed with the SEC for more information about BLAC and the security holdings of its officers and directors and their respective interests as security holders in the consummation of the transactions described herein. The proxy statement/prospectus for the proposed business combination, once available, and BLAC's other reports can be obtained, without charge, at the SEC's web site (http://www.sec.gov).
Contact:
Kuk Hyoun Hwang
Chief Executive Officer
Bellevue Life Sciences Acquisitions Corp.
group@bellevuecm.com
View original content:https://www.prnewswire.com/news-releases/bellevue-life-sciences-acquisitions-corp-reminds-stockholders-to-vote-in-favor-of-extension-at-may-14-2024-stockholder-meeting-302143389.html
SOURCE Bellevue Life Sciences Acquisitions Corp.
FAQ
When is the reconvened Special Meeting for BLAC?
The reconvened Special Meeting for Bellevue Life Sciences Acquisitions Corp. (BLAC) is scheduled for 9:00 a.m. Pacific time on Tuesday, May 14, 2024.
What is the purpose of the Extension Amendment Proposal for BLAC?
The purpose of the Extension Amendment Proposal is to extend the deadline by which BLAC has to consummate a business combination with OSR Holdings Co., from May 14, 2024, to November 14, 2024.
How can BLAC stockholders vote on the Extension Amendment Proposal?
Stockholders can vote on the Extension Amendment Proposal by submitting their proxy votes electronically or by telephone as per the instructions provided in the proxy materials.
What happens if BLAC does not receive 65% of votes for the Extension Amendment Proposal?
If BLAC does not receive votes representing at least 65% of its outstanding shares for the Extension Amendment Proposal, it may need to commence the liquidation process, impacting potential business combination opportunities.
How can stockholders withdraw redemption requests for BLAC shares?
Stockholders who wish to withdraw redemption requests for BLAC shares can contact the transfer agent, Continental Stock Transfer & Trust Company, before the Special Meeting on May 14, 2024, to request the return of their shares.
